- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04886284
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia (CERT)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cefazolin is licensed in Canada for the management of infections due to susceptible Staphylococcus aureus, including bacteremia. It has been commonly used for decades in this disease and, when compared in observational studies to anti-staphylococcal penicillins, has demonstrated reduced mortality.
Nevertheless, in the treatment of methicillin-susceptible S. aureus (MSSA) bacteremia, there remains significant opportunities to improve clinical outcomes. Indeed, S. aureus bacteremia kills more Canadians annually than myeloma, melanoma, renal, ovarian or stomach cancers. Overall mortality approached 18% in a recent Canadian clinical trial performed by our group (Cheng et al, 2020).
The duration of bacteremia, particularly after antibiotherapy is recognized as a major risk factor for mortality. Interventions which reduce the duration of bacteremia, without increasing the frequency of renal failure like gentamicin (Cosgrove et al, 2009) or the combination of vancomycin and flucloxacillin in MRSA (Tong et al, 2020), are among the most promising candidates for larger phase 3 studies designed to impact patient mortality.
Ertapenem is a commonly used antibiotic which has been on the Canadian market for more than 15 years. It is most commonly used in patients with infections caused by extended-spectrum beta-lactamase producing Enterobacteraciae; however, it has a broad spectrum of activity including Gram-positive bacteria such as S. aureus. Indeed, the drug is licensed in Canada for the treatment of complicated skin and soft tissue infections commonly caused by S. aureus.
In S. aureus the carbapenem antibiotics like ertapenem have exceptional affinity to the essential penicillin-binding protein (PBP), PBP1, exceeding even that of the antistaphylococcal β-lactams (Chambers et al, 1990). This complements the relative PBP2 proclivity of cefazolin (Bamberger et al, 2002).
The combination of cefazolin with ertapenem has also been shown to be synergistic in vitro (Sakoulas et al, 2016), in vivo in the mouse and rat models (Sakoulas et al, 2016; Ulloa et al, 2020), and in a small human case series (Ulloa et al, 2020).
Based on this data, there is compelling theory (attack on 2 PBPs), in vitro, in vivo, and human case evidence to support an exploratory phase 2 RCT of cefazolin-ertapenem for the treatment of MSSA bacteremia.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sarah Elsayed
- Phone Number: 23730 514-934-1934
- Email: sarah.elsayed@idtrials.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H4A3J1
- McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult >=18 years old
S. aureus bacteremia within the past 48 hours:
- with any unknown MRSA status (in centers with <15% prevalence of MRSA in their annual blood cultures) or known negative MRSA screening swab within 90 days OR
- which has already been shown to be MSSA
- Current receipt of cefazolin or where it would be clinically appropriate (according to treating ID specialist) to switch to cefazolin as the backbone therapy (open label, non-study drug).
NOTE: Up to an additional 12-24 hours of open label non-study VANCOMYCIN, LINEZOLID or DAPTOMYCIN may be allowed if there is sepsis and clinical concern for MRSA has not been excluded.
Exclusion Criteria:
Clinical:
- At time of recruitment, the patient has already clinically improved with at least one subsequent negative culture at >24 hours incubation
- Anaphylaxis to any beta-lactam antibiotic (and any allergy to ertapenem) Polymicrobial bacteremia (not including skin commensals)
- Known seizure disorder
- Any receipt of valproic acid
- Expected mortality within 48 hours
- Need for critical care resources but "do not resuscitate" status precludes the receipt of critical care
- Unable to provide informed consent and no available healthcare proxy (with ethics approval for deferred consent in cases of severe illness)
Administrative:
- Refusal to provide informed consent
- Refusal of healthcare team to participate
- No reliable means of outpatient contact (telephone/email/text)
- Previously enrolled
- Patients whose isolate is identified as MRSA post-enrollment will be subsequently excluded (see below).
Note that because MSSA is much more common than MRSA in Canada (90% of all S. aureus bacteremia at MUHC, for example, are MSSA and in the presence of a negative MRSA screening swab or unknown MRSA status, this means that the risk of MRSA is less than 5%). We believe time to combination therapy is likely linked to benefit, therefore we will recruit the patients as soon as S. aureus is identified but potentially prior to confirmation the organism is MSSA. Where possible, rapid MRSA detection techniques will be deployed; however with conventional screening this will mean approximately a 12-24 hours delay. Organisms subsequently identified as MRSA will be excluded from the intention to treat analysis and the sample size will be adjusted accordingly to ensure the total enrollment meets study goals.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ertapenem
Ertapenem 1g IV daily infused over 2 hours x 5 days
|
Adjunctive ertapenem
Other Names:
|
Placebo Comparator: Placebo
Saline placebo infused daily over 2 hours x 5 days
|
Saline placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success
Time Frame: Day 5
|
Composite of: Patient alive, fever resolved, blood cultures negative for S. aureus, systolic blood pressure >=90mmHg not on vasopressors
|
Day 5
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood culture clearance
Time Frame: 30 days
|
Time between first positive and first negative blood culture
|
30 days
|
Clinical improvement
Time Frame: 30 days
|
Time to clinical improvement defined as the time until fever resolved, blood cultures sterile, and systolic blood pressure >=90mmHg not on vasopressors in patients who survive to clinical improvement
|
30 days
|
Length of stay
Time Frame: 90 days
|
The time from initial emergency room visit until discharge from hospital in patients discharged alive
|
90 days
|
All cause-mortality
Time Frame: 90 days
|
Death from any cause
|
90 days
|
C. diff infection
Time Frame: 56 days
|
Any C. difficile infection within 56 days
|
56 days
|
Gram-negative bacteremia
Time Frame: 56 days
|
Any Gram-negative bacteremia within 56 days
|
56 days
|
New colonization with carbapenemase producing organisms
Time Frame: 56 days
|
Newly identified colonization with carbapenemase producing organisms to day 56
|
56 days
|
Valve replacement surgery
Time Frame: 56 days
|
Any valve replacement surgery occurring after the initial diagnosis
|
56 days
|
Recurrent isolation of MSSA from a sterile site
Time Frame: Between Days 6 and 90 inclusive
|
Any positive culture of MSSA from a sterile site (blood, cerebral spinal fluid, joint aspirate, bone, etc.) occurring after the end of combination therapy
|
Between Days 6 and 90 inclusive
|
Seizure
Time Frame: 7 days
|
Any clinically identified seizure within 48 hours of discontinuation of combination therapy
|
7 days
|
Acute Kidney Injury
Time Frame: 7 days
|
An increase in serum creatinine to ≥1.5 times baseline OR new requirement for hemodialysis at any time in the first 7 days from randomization
|
7 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health-related quality of life
Time Frame: 90 days
|
This will be assessed using the EQ-5D-5L questionnaire
|
90 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emily G McDonald, MD MSc, Research Institute of the McGill University Health Centre
- Principal Investigator: Matthew P Cheng, MD, Research Institute of the McGill University Health Centre
Publications and helpful links
General Publications
- Ulloa ER, Singh KV, Geriak M, Haddad F, Murray BE, Nizet V, Sakoulas G. Cefazolin and Ertapenem Salvage Therapy Rapidly Clears Persistent Methicillin-Susceptible Staphylococcus aureus Bacteremia. Clin Infect Dis. 2020 Sep 12;71(6):1413-1418. doi: 10.1093/cid/ciz995.
- Sakoulas G, Olson J, Yim J, Singh NB, Kumaraswamy M, Quach DT, Rybak MJ, Pogliano J, Nizet V. Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6609-6618. doi: 10.1128/AAC.01192-16. Print 2016 Nov.
- Cosgrove SE, Vigliani GA, Fowler VG Jr, Abrutyn E, Corey GR, Levine DP, Rupp ME, Chambers HF, Karchmer AW, Boucher HW. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic. Clin Infect Dis. 2009 Mar 15;48(6):713-21. doi: 10.1086/597031.
- Bamberger DM, Herndon BL, Fitch J, Florkowski A, Parkhurst V. Effects of neutrophils on cefazolin activity and penicillin-binding proteins in Staphylococcus aureus abscesses. Antimicrob Agents Chemother. 2002 Sep;46(9):2878-84. doi: 10.1128/AAC.46.9.2878-2884.2002.
- Chambers HF, Sachdeva M. Binding of beta-lactam antibiotics to penicillin-binding proteins in methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Jun;161(6):1170-6. doi: 10.1093/infdis/161.6.1170.
- Cheng MP, Lawandi A, Butler-Laporte G, De l'Etoile-Morel S, Paquette K, Lee TC. Adjunctive Daptomycin in the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Randomized, Controlled Trial. Clin Infect Dis. 2021 May 4;72(9):e196-e203. doi: 10.1093/cid/ciaa1000.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Sepsis
- Bacteremia
- Endocarditis
- Staphylococcal Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Ertapenem
Other Study ID Numbers
- 2021-7400
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus Bacteremia
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
ContraFectCompletedStaphylococcus Aureus Bacteremia | Staphylococcus Aureus EndocarditisUnited States, Belgium, Bulgaria, Chile, Czechia, France, Germany, Greece, Guatemala, Israel, Italy, Russian Federation, Spain, United Kingdom
-
University of PennsylvaniaWithdrawnStaphylococcus Aureus Bacteremia | Staphylococcus Aureus EndocarditisUnited States
-
University Medicine GreifswaldRecruitingStaphylococcus Aureus BacteremiaGermany
-
University of MelbourneRadboud University Medical Center; Sunnybrook Health Sciences Centre; UMC Utrecht and other collaboratorsRecruitingStaphylococcus Aureus BacteremiaAustralia, New Zealand, Canada, Singapore, Netherlands, Israel
-
Thomas BenfieldUnknownStaphylococcus Aureus BacteremiaDenmark
-
Bristol-Myers SquibbCompleted
-
Clinical Research Centre, MalaysiaNot yet recruitingStaphylococcus Aureus BacteremiaMalaysia
-
Sunnybrook Health Sciences CentreMcGill University Health Centre/Research Institute of the McGill University...RecruitingStaphylococcus Aureus BacteremiaCanada
Clinical Trials on Ertapenem
-
University Medical Center GroningenCompleted
-
University of MichiganCompletedAcute Kidney FailureUnited States
-
Catholic University of the Sacred HeartMerck Sharp & Dohme LLCUnknown
-
Merck Sharp & Dohme LLCCompleted
-
Hartford HospitalMerck Sharp & Dohme LLCCompletedHealthyUnited States
-
Klinikum Hanover-Siloah HospitalUnknownAcute Disease | Diverticulitis, ColonicGermany
-
Prince of Songkla UniversityUnknownPatients With Urosepis and Received Ertapenem for TreatmentThailand
-
Merck Sharp & Dohme LLCCompleted
-
Albany College of Pharmacy and Health SciencesMerck Sharp & Dohme LLCCompletedEnd Stage Renal Disease | Continuous Ambulatory Peritoneal DialysisUnited States